Barbara Borden

Cooley's 2023 Activism Year In Review: Wolf Packs At The Gate

Cooley's 2023 Cross-Border M&A Year In Review: Navigating Choppy Waters Into A More Buoyant 2024

Cooley's 2023 Life Sciences M&A Year In Review: Potent Mix Of Creativity And Resilience Spurs Activity Heading Into 2024

Apples, Oranges And Lemonade: Pursuing Multiple Strategic Alternatives In The Public Company Boardroom

Keeping Up With M&A Case Law – Spotlight On Recent Delaware Decisions

Cooley's 2022 Tech M&A Year In Review

Delaware Advance Notice Decisions Highlight Move Toward Enhanced Scrutiny Of Board Actions, Even Where Conflicts Exist

ESG And M&A: Vetting A Target's ESG Strengths And Weaknesses To Assess Value, Go-Forward Risks And Disclosure Requirements

Delaware (Again!) Requires Upward Adjustment To Deal Price In Appraisal Proceeding Despite Objectively Fair Sales Process

Cooley's 2021 Life Sciences M&A Year In Review